Replimune (REPL.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov7

Replimune Group's IGNYTE Clinical Trial Shows PD-1 Resistance Reversal

21:45

Replimune Publishes Clinical Research Document on Non-Small Cell Skin Cancer and MSI-H/dMMR Solid Tumors

14:10

Replimune released FY2026 Q2 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 500K), actual EPS USD -0.904 (forecast USD -0.787)

04:00

Replimune released FY2026 Semi-Annual earnings on November 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.8512

04:00

Oct29

HC Wainwright Maintains Replimune Group 'Buy' Rating, Projects Earnings Per Share of $0.53

11:08

Oct27

Replimune Group's RP1 Application Accepted by FDA

10:32

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2026 Q2 Earning Release (USD) Net Income -83.1 M, EPS -0.904

Aug7

Earning Release(EST)

FY2026 Q1 Earning Release (USD) Net Income -86.69 M, EPS -0.9472

May22

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Net Income -74.13 M, EPS -0.8153

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change